Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ono Licenses Epilepsy Med from South Korean Biopharma
Ono Pharmaceutical said on October 13 that it has acquired exclusive rights to develop and commercialize South Korea-based SK Biopharmaceuticals’ antiepileptic drug cenobamate in Japan. Cenobamate was approved in the US in November last year for the treatment of partial-onset…
To read the full story
Related Article
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
- Ono Set for Japan Filing of SK Bio’s Epilepsy Med in FY2025
December 11, 2024
BUSINESS
- Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
- Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
- Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
- Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…